Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Novel uses of androgen receptor inhibitors in cancer

Description:

Problem: 
For many cancer types, women have lower incidence and better outcomes than men. The role of sex steroid hormones, such as estrogen and testosterone, has been studied in reproductive organ cancers such as prostate and breast cancer, but not in other non-androgen (AR)-driven cancers. Recent studies have shown that testosterone promotes cancer cell proliferation. 

 

 

Solution: 

Inhibiting testosterone-induced tumor growth as a new therapeutic approach for non-AR-driven cancer. 

 

 

Technology Overview: 

Dr. Ridky and colleagues demonstrated that testosterone promotes cancer cell proliferation through a non-AR-dependent mechanism.  Four existing FDA-approved androgen receptor inhibitors, flutamide, bicalutamide, enzalutamide, and apalutamide, are inhibiting the proliferation of different cancer cell lines, from non-reproductive non-AR expressing tissues. Hence these therapeutics may have a way broader therapeutics effect than earlier contemplated. 

 

Both bicalutamide (CDX) and enzalutamide (ENZ) completely block testosterone-induced proliferation of melanoma cell lines.

 

Advantages: 

Enhance effectiveness of current cancer therapy treatment using already approved drugs 

 

 

Stage of Development: 

Preclinical Discovery

 

 

Intellectual Property: 

Patent application filed

 

Desired Partnerships: 

Sponsored research and licensing

 

 

Docket # 20-9153

 

 

Download pdf

 


Patent Information:
For Information, Contact:
Viviane Martin
University of Pennsylvania
215-746-4275
martinv@upenn.edu
Inventors:
Todd Ridky
Cristina Aguirre Portol├ęs
Christopher Natale
Keywords:
Oncology